

Summary of Utilization Management (UM) Program Changes

January #2 2021

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Dojolvi</i>	triheptanoin	<p>Dojolvi is indicated for long-chain fatty acide oxidation disorder (LC-FAOD).</p> <p>Initial criteria requires: 1) Diagnosis of a long-chain fatty acid oxidation disorder (LC-FAOD) AND 2) Disease has been molecularly confirmed (i.e., genetic testing) AND 3) Not used with any other medium-chain triglyceride (MCT) product AND 4) Prescribed by a clinical specialist knowledgeable in appropriate disease-related dietary management (e.g., geneticist, cardiologist, gastroenterologist, etc.)</p>	New	4/01/2021
<i>Mycapssa (in Octreotide Products)</i>	octreotide	<p>New oral octreotide capsule approved as long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.</p> <p>Initial criteria requires: 1) Diagnosis of acromegaly 2) One of the following: <i>either</i> inadequate response to surgery or pituitary radiation therapy, <i>or</i> not a candidate for surgical resection or pituitary radiation therapy; 3) Patient has responded to and tolerated treatment with octreotide or lanreotide.</p>	Update	4/01/2021
<i>Botox</i>	onabotulinumtoxin A	<p>Expanded indication: treatment of spasticity in patients 2 years of age and older.</p> <p>Modified criteria to simply state diagnosis of spasticity (remove reference to lower and upper limb spasticity).</p>	Update	4/01/2021

<i>Dysport</i>	abobotulinumtoxin A	Expanded indication: treatment of spasticity in patients 2 years of age and older. Modified criteria to simply state diagnosis of spasticity (remove reference to lower and upper limb spasticity).	Update	4/01/2021
<i>Tremfya</i>	guselkumab	New indication for treatment of adult patients with active psoriatic arthritis. Initial criteria requires: 1) diagnosis of active psoriatic arthritis (PsA) 2) Prescribed by dermatologist or rheumatologist.	Update	2/18/2021
<i>Actemra</i>	tocilizumab	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021
<i>Orencia</i>	abatacept	Update to remove Simponi Aria one of the first line trial and failure options for rheumatoid arthritis, psoriatic arthritis indication. Simponi is still an option.	Update	4/01/2021
<i>Enbrel</i>	etanercept	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis indications. Simponi is still an option. The criteria will no longer have separate sections based on age.	Update	4/01/2021
<i>Kevzara</i>	sarilumab	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021
<i>Kineret</i>	anakinra	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021
<i>Olumiant</i>	baricitinb	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021

<i>Rituxan Truxima (in Rituximab)</i>	rituximab rituximab-abbs	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021
<i>Xeljanz/XR</i>	tofacitinib	Update to remove Simponi Aria one of the first line trial and failure options for psoriatic arthritis indication. Simponi is still an option. Tremfya has been added as another first line option for psoriatic arthritis. Remove infliximab as one of the trial and failure options for ulcerative colitis.	Update	4/01/2021
<i>Taltz</i>	ixekizumab	Update to remove Simponi Aria as one of the first line trial and failure options for psoriatic arthritis and ankylosing spondylitis indications. Simponi is still an option.	Update	4/01/2021
<i>Cosentyx</i>	secukinumab	Update to remove Simponi Aria one of the first line trial and failure options for psoriatic arthritis and ankylosing spondylitis indication. Simponi is still an option.	Update	4/01/2021
<i>Entyvio</i>	vedolizumab	Update to remove infliximab as one of the trial and failure options for ulcerative colitis and Crohn's disease.	Update	4/01/2021
<i>Ilumya</i>	tildrakizumab-asmn	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidence by one of the following: 1) Reduction of body surface area involvement from baseline 2) Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021
<i>Otezla</i>	apremilast	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidenced by one of the following: 1) Reduction of body surface area involvement from baseline 2) Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021

<i>Siliq</i>	brodalumab	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidenced by one of the following: 1) Reduction of body surface area involvement from baseline 2) Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021
<i>Skyrizi</i>	risankizumab-rzaa	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidenced by one of the following: 1) Reduction of body surface area involvement from baseline 2) Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021
<i>Stelara</i>	ustekinumab	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidenced by one of the following: Reduction of body surface area involvement from baseline Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021
<i>Isturisa</i>	osilodrostat	Requirement of trial and failure to 90 days of ketoconazole tablets.	Update	4/01/2021
<i>Sabril Vigadrone</i>	vigabatrin	Allow <i>either</i> the trial and failure of two formulary anticonvulsants <i>or</i> for continuation of therapy.	Update	4/01/2021
<i>Copper Chelating Agents</i>	trientine pencillamine	For Cuprimine, generic penicillamine, Syprine, trientine, Clovique for Wilson's Disease, added Documentation of one of the following diagnostic tests: <ol style="list-style-type: none">1) Presence of Kayser-Fleisher rings2) Serum ceuloplasim (CPN) less than 20 mg/dL2) 24-hour urinary copper excretion greater than 100 mcg	Update	4/01/2021

		<p>3) Liver biopsy with copper dry weight greater than 250 mcg/g</p> <p>4) ATP7B mutation via genetic testing AND Prescribed by gastroenterologist or hepatologist</p> <p>For Cuprimine and generic penicillamine for cystinuria indication, added:</p> <p>1) Requirement of trial and failure of urinary alkalization therapy</p> <p>2) Prescribed by nephrologist or urologist</p> <p>For Cuprimine and generic penicillamine for rheumatoid arthritis indication must be prescribed by rheumatologist.</p>		
<i>Provigil</i>	Modafinil	An exception to the quantity limit to allow for twice daily dosing for use in excessive somnolence-narcolepsy.	Update	4/01/2021
<i>Nubeqa</i>	daralutamide	Reauthorization criteria will state 'patient does not show evidence of progressive disease while on therapy.'	Update	4/01/2021